Kaisa Health Group Holdings Limited has issued a notice convening a Special General Meeting (SGM) on 1 September 2026, 11:00 a.m., at Conference Room Cambridge Lab, 19/F., Office Plus@Sheung Wan, Hong Kong.

The sole agenda item is a special resolution proposing to: • Change the English name from “Kaisa Health Group Holdings Limited” to “Qinghai Biotech Pharmaceutical Group Limited”. • Adopt “青海生物製藥集團有限公司” as the new Chinese secondary name, replacing “佳兆業健康集團控股有限公司”.

The rebranding will take effect after the Registrar of Companies in Bermuda issues the relevant certificate of incorporation on change of name and certificate of secondary name. Any one director is authorised to execute all documents and handle filings required to implement the name change in Bermuda and Hong Kong.

Key meeting logistics: • Proxy submission deadline: no later than 48 hours before the meeting (29 August 2026, 11:00 a.m.). • Register of members closure: 27 August 2026 to 1 September 2026, both dates inclusive. • Record date for voting rights: 1 September 2026. • Share transfers for voting eligibility must be lodged by 4:30 p.m. on 26 August 2026. • All resolutions will be decided by poll.

Contingency arrangements address severe weather; if Typhoon Signal No. 8 or higher, an “extreme conditions” announcement, or a Black Rainstorm Warning is in force three hours before the scheduled time, the SGM will be postponed with further details to be announced.

As of the notice date (13 August 2026), the Board comprises six executive directors, including Chairman and Executive Director Kwok Ying Shing, and three independent non-executive directors.